Methods of expanding myeloid cell populations and uses thereof

Abstract

The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation.

What is claimed is: 
     
         1 . A method of improving impaired hematopoiesis in a human, comprising,
 administering to the human a composition comprising human allogeneic myeloid progenitor cells derived from multiple unrelated donors in an amount sufficient to improve hematopoiesis in the human, wherein there is at least a partial mismatch at a major histocompatability complex (MHC) gene between the donors and the human.   
     
     
         2 . The method of  claim 1 , wherein the composition has less than 10% .hematopoietic stem cells (HSCs). 
     
     
         3 . The method of  claim 1 , wherein human allogeneic myeloid progenitor cells are expanded human allogeneic myeloid progenitor cells. 
     
     
         4 . The method of  claim 1 , wherein the myeloid progenitor cells comprise common myeloid progenitor cells. 
     
     
         5 . The method of  claim 1 , wherein myeloid progenitor cells in the composition are at least 25% of total cells in the composition. 
     
     
         6 . The method of  claim 1 , wherein the human is undergoing hematopoietic stem cell (HSC) transplantation. 
     
     
         7 . The method of  claim 6 , wherein the expanded myeloid progenitor cells are administered after the HSC transplantation 
     
     
         8 . The method of  claim 6 , wherein the expanded myeloid progenitor cells are administered concurrently with HSC transplantation. 
     
     
         9 . The method of  claim 1 , wherein the human is neutropenic. 
     
     
         10 . The method of  claim 1 , wherein the human is suffering from thrombocytopenia. 
     
     
         11 . The method of  claim 10 , wherein the expanded myeloid progenitor cells are administered adjunctively with a therapeutic composition for treating complications associated with thrombocytopenia. 
     
     
         12 . The method of  claim 11 , wherein the therapeutic composition comprises a platelet preparation. 
     
     
         13 . The method of  claim 11 , wherein the therapeutic composition comprises EPO. 
     
     
         14 . The method of  claim 1 , wherein the myeloid progenitor cells are expanded from cells obtained from peripheral blood. 
     
     
         15 . The method of  claim 1 , wherein the myeloid progenitor cells are expanded from cells obtained from bone marrow. 
     
     
         16 . The method of  claim 1 , wherein the myeloid progenitor cells are expanded from cells obtained from umbilical cord blood or placental cord blood. 
     
     
         17 . The method of  claim 1 , wherein the human has been previously treated with or exposed to a myeloablative agent. 
     
     
         18 . The method of  claim 17 , wherein the myeloablative agent is ionizing radiation.